Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance (original) (raw)
Related papers
Journal of Internal Medicine, 2012
Background: CD36 is a widely expressed cell surface receptor, that among other ligands binds lipoproteins, and its function has been implicated in many of the complications belonging to the metabolic syndrome. We have previously identifi ed a circulating form of CD36 and established an inhouse ELISA assay for measurement of CD36 in plasma. Plasma CD36 was elevated in insulin resistant obese and diabetic patients, and in patients with unstable atherosclerotic plaques. The objective of this study was to compare two new commercial CD36 ELISA assays and our in-house ELISA assay. Methods: CD36 was measured in 30 plasma samples from 10 individuals by the in-house and the two commercial assays (Cusabio Biotech and Adipobioscience). Results: Our results demonstrate that there is an absolute incongruity between the three assays. The incongruity could not be explained by different pre-analytical procedures in assay protocols. Conclusions: The lack of correlation indicates that measurement of CD36 levels in plasma is not trivial. The two commercial assays are not appropriate for CD36 detection in plasma and it seems unlikely that the established pathophysiological association with elevated plasma CD36 can be reproduced.
Assessment of sCD36 levels and Lipids in Type II Diabetes Mellitus
Background: Cluster determinant 36 (CD36) is a fatty acid translocase which is expressed in variety of cells. Increased expression of CD36 is observed in liver, adipose tissue and skeletal muscle. Non-cell bound CD36 was identified in human plasma and was termed soluble CD36(sCD36) and its level parallels with the increased expression of CD36 observed in various cell types. In diabetes mellitus (DM) the cellular uptake of fatty acids is increased and is associated with insulin resistance and atherosclerosis. Various studies showed elevated sCD36 its association with insulin resistance and atherosclerosis. The aim of the present study is to determine the association of sCD36 with type II DM. Methods: This was a cross-sectional study, and participants were classified as healthy controls and T2DM patients. We estimated FPG, HbA1c, and lipids in them. A quantitative ELISA was used to assess sCD36 levels. Correlation analysis was performed between sCD36 and Triglycerides (TG). Results: A total of 65 subjects were included, 25 healthy controls and 40 T2DM were included in the study. Elevated levels of sCD36, HbA1c and lipids was observed in cases when compared to controls. Median serum concentrations of sCD36 in healthy controls and type 2 Diabetics are 254 and 462 ng/L respectively and it is statistically significant (p 0.01). The median values for FPG, TG, VLDL in cases were 152.5 (mg/dL), 154.5 (mg/dL) and 31 (mg/dL) respectively and it is significantly higher in cases than controls. But there was no significant association between CD36 & TG. Conclusion: Soluble CD36 (sCD36) identified in human plasma is associated with insulin resistance, Type II DM, atherosclerosis and plasma sCD36 levels reflects its tissue expression. In our study we observed elevated sCD36 levels in type II DM when compared to controls. The findings of our study suggests sCD36 may be used as a marker of insulin resistance.
Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity
Diabetes, 2007
OBJECTIVE-The etiology of type 2 diabetes often involves diet-induced obesity (DIO), which is associated with elevated plasma fatty acids and lipoprotein associated triglycerides. Since aberrant hepatic fatty acid uptake may contribute to this, we investigated whether increased expression of a fatty acid transport protein (CD36) in the liver during DIO contributes to the dyslipidemia that precedes development of type 2 diabetes.
Journal of Clinical Medicine, 2019
The aim of this study was to determine whether plasma concentrations of sCD36 (soluble CD36) are associated with the presence of type 1 or type 2 diabetes. Plasma levels of sCD36 were analysed in 1023 subjects (225 type 1 diabetes (T1D) patients, 276 type 2 diabetes (T2D) patients, and 522 non-diabetic control subjects) using an enzyme-linked immunosorbent assay (ELISA). Multinomial and logistic regression models were performed to evaluate associations with sCD36 and its association with diabetes types. There were no significant differences in sCD36 (p = 0.144) among study groups, neither in head-to-head comparisons: non-diabetic versus T1D subjects (p = 0.180), non-diabetic versus T2D subjects (p = 0.583), and T1D versus T2D patients (p = 0.151). In the multinomial model, lower sCD36 concentrations were associated with older age (p < 0.001), tobacco exposure (p = 0.006), T2D (p = 0.020), and a higher-platelets count (p = 0.004). However, in logistic regression models of diabetes...
The Journal of Lipid Research, 2003
CD36 (fatty acid translocase) is involved in highaffinity peripheral fatty acid uptake. Mice lacking CD36 exhibit increased plasma free fatty acid and triglyceride (TG) levels and decreased glucose levels. Studies in spontaneous hypertensive rats lacking functional CD36 link CD36 to the insulin-resistance syndrome. To clarify the relationship between CD36 and insulin sensitivity in more detail, we determined insulin-mediated whole-body and tissue-specific glucose uptake in CD36-deficient (CD36 ؊ / ؊ ) mice.
Scientific Reports, 2015
Key features of the metabolic syndrome are insulin resistance and diabetes. The liver as central metabolic organ is not only affected by the metabolic syndrome as non-alcoholic fatty liver disease (NAFLD), but may contribute to insulin resistance and metabolic alterations. We aimed to identify potential associations between liver injury markers and diabetes in the population-based Heinz Nixdorf RECALL Study. Demographic and laboratory data were analyzed in participants (n = 4814, age 45 to 75y). ALT and AST values were significantly higher in males than in females. Mean BMI was 27.9 kg/m 2 and type-2-diabetes (known and unkown) was present in 656 participants (13.7%). Adiponectin and vitamin D both correlated inversely with BMI. ALT, AST, and GGT correlated with BMI, CRP and HbA1c and inversely correlated with adiponectin levels. Logistic regression models using HbA1c and adiponectin or HbA1c and BMI were able to predict diabetes with high accuracy. Transaminase levels within normal ranges were closely associated with the BMI and diabetes risk. Transaminase levels and adiponectin were inversely associated. Re-assessment of current normal range limits should be considered, to provide a more exact indicator for chronic metabolic liver injury, in particular to reflect the situation in diabetic or obese individuals.